We’re excited to announce that two of our Precision colleagues have been named to MM+M’s 40 Under 40 this year! Congratulations to Ashwin Athri, EVP, Managing Director, PRECISIONxtract, and Isabella Sergio, EVP, Managing Director, PRECISIONvalue. Now in its fourth year, 40 Under 40 honors the industry’s best-regarded young talent. We look forward to celebrating with Ashwin and Isabella, and all the other honorees, on February 16.
Congratulations to Precision’s Iver Jensen for his contributions to “Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome,” a study recently published in the Journal of Pediatric Pharmacology and Therapeutics. The study is the first cost-consequence analysis cost-consequence analysis comparing the clinical and health economic outcomes in newborns with RDS when using selective early surfactant treatment vs standard surfactant administration in the United States. Read the study here:
Recent headlines suggest that the biotech industry as a whole is experiencing a downturn, yet in spite of this narrative the momentum for advanced therapies continues to persevere. Many companies in the cell and gene therapy space are dedicated to bringing these novel therapies to the patients who need them. In this article for PM360 Magazine, Precision’s Anshul Mangal explores the breakthroughs taking place in autologous cell therapies, non-viral delivery methods, and gene editing technologies that may improve patient access for life-saving treatments.
The healthcare sector is hastening adoption of population health approaches, including initiatives to improve outcomes by closing health disparity gaps. Precision’s Maureen Hennessey, Ph.D., Jorge Font, Dominic Galante, M.D., Kris Kang, and Cynthia Miller, M.D. identify three trends to watch in 2023 to tackle pernicious social determinants of health challenges.
Regenerative medicines are evolving at breakneck speed—and every advance has far-reaching implications. To be effective in CGTx development, you also need to understand the current investment landscape, new and exciting technologies, and the latest progress in drug development, manufacturing, regulatory, and reimbursement.
Sponsored by Precision ADVANCE, this Endpoints webinar with convene leading advanced therapy experts to discuss how to be effective in CGTx development. This discussion will be moderated by Anshul Mangal (President, Project Farma & Precision ADVANCE), and include insights from Phil Cyr (EVP, Precision Value & Health), David Greenwald (VP of Business Development, Deerfield Management), Rajul Jain (Managing Director, Vida Ventures), Joseph La Barge (CEO, Apertura Gene Therapy), and Adrian Woolfson (Executive Chairman, President & Co-Founder, Replay Bio).
As Congress moves to improve the accelerated approval process through the Accelerated Approval Integrity Act, we must understand its history and ways to mitigate unnecessary spending while maintaining access to innovative treatments. Precision’s Cynthia Miller warns of potential unintended consequences as Congress moves to improve the accelerated approval process.
Precision’s Dr. Dominic Galante will moderate the Quality Conversations Breakfast session on Day 2 of the NCQA Health Innovation Summit. “Digital Reshaping of the Diabetes Health-Care Ecosystem” will explore the promise of leveraging patient-generated data from CGMs to improve diabetes care, health equity, and the potential to augment diabetes quality measures that are reported and tracked by quality organizations. November 1 at 7:30AM ET.
Learn how to make your brands’ market access a top advantage over the competition. Join PRECISION’s Jon Bambalas, Jeff Becker and Thad Nowakowski at this year’s Managed Markets & Account Management Strategies Conference for “Make Market Access Your Brand’s Super Power,” October 27 at 9:30 AM CT.
Patient support programs, like HUB services, Patient Assistance Programs (PAP), Bridge programs or copay support, have become increasingly important in making prescription drugs more affordable and accessible. Yet an IQVIA study found that 31% of patients abandon their prescription if a coupon is not available compared with only 12% of new patients walked away from their prescriptions if a copay coupon was available to them.
Prescription abandonment continues to be a significant issue.
In this insightful webinar from PRECISIONxtract, you’ll hear how life science brand leaders can leverage EHR systems to dramatically increase successful enrollment for patient support programs.
Attendees will hear about:
Join us for this unique, solution-based discussion— a great fit for pharma manufacturers looking to get their brands’ patient resources in front of HCPs where those HCPs are in the moment of care — inside the EHR!
At this years Meeting on the Mesa’s conference, Anshul Mangal: President (Precision ADVANCE and Project Farma) sat down with leading industry experts to discuss the future of cell and gene therapies.
This panel, sponsored by Precision ADVANCE, will feature insights from industry leaders on the future of advanced therapies including innovations in clinical trials, going from treating rare diseases to prevalent conditions, and implementing next-generation gene-editing technologies. The panelists will also discuss manufacturing and talent bottlenecks and the evolution of reimbursement payment models.
Moderated by Anshul Mangal (President of Project Farma & Precision ADVANCE), this discussion will feature insights from Stewart Abbot: (Chief Scientific Officer, Turnstone Biologics), Andrew Knudten: (Chief Operating Officer, Jaguar Gene Therapy), Laura Lande-Diner: (Chief Business Officer, Satellite Bio), Robert Peters: (Chief Scientific Officer, Ensoma), and Deborah Phippard: (Chief Scientific Officer, Precision for Medicine).
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
